Request This Service

The Translational Core provides consultation, expertise, staff and infrastructure for assay development/screening and first-in-animal studies to support probe/lead optimization and prioritization. Screening activities include the development and implementation of biochemical, cell-based and whole animal screens using both commercially available libraries (FDA-approved drugs, strategic mechanism-based sets, and broader chemical/functional diversity sets) and the proprietary Natural Products Repository. The core also supports probe/lead preformulation/dosing, bioanalytical assay development, metabolism, biodistribution, pharmacokinetics (PK), pharmacodynamics (PD) and basic toxicology (MTD) studies. The core operates under the co-directorship of Professors Markos Leggas and Brad Anderson with a current staff of one M.S. level and two Ph.D. level scientists.